17,001 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,001 shares of the biopharmaceutical company’s stock, valued at approximately $88,000.

Several other institutional investors have also added to or reduced their stakes in the business. Arizona State Retirement System lifted its holdings in Revance Therapeutics by 27.6% during the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,996 shares during the last quarter. Sei Investments Co. lifted its holdings in Revance Therapeutics by 52.5% during the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 7,628 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Revance Therapeutics by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 7,890 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Revance Therapeutics by 9.8% during the first quarter. California State Teachers Retirement System now owns 97,493 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 8,668 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Revance Therapeutics by 29.4% during the second quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 9,601 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Trading Up 5.1 %

RVNC stock opened at $3.92 on Wednesday. The company’s 50 day moving average is $4.86 and its 200 day moving average is $4.46. The stock has a market cap of $411.21 million, a price-to-earnings ratio of -2.03 and a beta of 0.81. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. As a group, sell-side analysts forecast that Revance Therapeutics, Inc. will post -1.54 EPS for the current fiscal year.

Analyst Ratings Changes

RVNC has been the topic of several analyst reports. Piper Sandler cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. StockNews.com initiated coverage on Revance Therapeutics in a research report on Wednesday. They set a “hold” rating on the stock. Barclays reiterated an “equal weight” rating and set a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Guggenheim reiterated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $9.66.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.